Several brokerages have updated their recommendations and price targets on shares of HTG Molecular Diagnostics (NASDAQ: HTGM) in the last few weeks:
- 7/18/2017 - HTG Molecular Diagnostics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “
- 7/17/2017 - HTG Molecular Diagnostics was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
- 7/6/2017 - HTG Molecular Diagnostics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
- 6/29/2017 - HTG Molecular Diagnostics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock. They wrote, “We note that the launch of this new assay comes on schedule and expands the company’s existing menu following the launch of HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assays for research use. Investors may recall that this assay was designed for retrospective gene expression profiling (GEP) to complement traditional immunohistochemistry (IHC) testing, allowing investigators to assess mRNA expression of large numbers of biomarkers—up to 470 mRNA targets in this case—when formalin-fixed, paraffin-embedded (FFPE) sample availability is limited. Importantly, small and minimally invasive tissue biopsies are the trend nowadays in diagnostics, and within this setting, EdgeSeq PATH Assay allows for a more comprehensive profiling than conventional IHC. This may potentially lead to new GEP-based diagnostic or prognostic tests in oncology and beyond, in our view.””
Shares of HTG Molecular Diagnostics, Inc. (NASDAQ HTGM) opened at 2.37 on Thursday. The stock’s market cap is $22.57 million. HTG Molecular Diagnostics, Inc. has a 1-year low of $1.20 and a 1-year high of $13.25. The company’s 50-day moving average price is $2.87 and its 200 day moving average price is $3.36.
HTG Molecular Diagnostics (NASDAQ:HTGM) last released its earnings results on Monday, May 15th. The medical research company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.15. HTG Molecular Diagnostics had a negative return on equity of 1,538.49% and a negative net margin of 440.31%. The firm had revenue of $1.37 million for the quarter, compared to the consensus estimate of $2.44 million. Equities analysts forecast that HTG Molecular Diagnostics, Inc. will post ($2.25) EPS for the current fiscal year.
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
